
## Andrew Lees

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6400904/publications.pdf

Version: 2024-02-01



ANDREWLEES

#	Article	IF	CITATIONS
1	Harnessing galactose oxidase in the development of a chemoenzymatic platform for glycoconjugate vaccine design. Journal of Biological Chemistry, 2021, , 101453.	3.4	8
2	Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) for Use in Protein–Polysaccharide Conjugate Vaccines and Immunological Reagents. III Optimization of CDAP Activation. Vaccines, 2020, 8, 777.	4.4	8
3	Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230. Vaccine, 2020, 38, 5480-5489.	3.8	15
4	Analytical Comparability Assessments of 5 Recombinant CRM 197 Proteins From Different Manufacturers and Expression Systems. Journal of Pharmaceutical Sciences, 2018, 107, 1806-1819.	3.3	31
5	Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. Molecular Pharmaceutics, 2018, 15, 4947-4962.	4.6	40
6	Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE, 2018, 13, e0203143.	2.5	67
7	Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate Formulation. Molecules, 2018, 23, 1749.	3.8	22
8	Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005493.	3.0	44
9	Contactâ€dependent suppression of <scp>CD</scp> 4 Tâ€cell activation and proliferation by B cells activated through IgD crossâ€linking. Immunology, 2015, 144, 444-452.	4.4	0
10	Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum. Vaccine, 2014, 32, 6107-6114.	3.8	7
11	A scalable method for biochemical purification of Salmonella flagellin. Protein Expression and Purification, 2014, 102, 1-7.	1.3	31
12	Novel Synthetic (Poly)Glycerolphosphate-Based Antistaphylococcal Conjugate Vaccine. Infection and Immunity, 2013, 81, 2554-2561.	2.2	16
13	The Nature of an In Vivo Anti-Capsular Polysaccharide Response Is Markedly Influenced by the Composition and/or Architecture of the Bacterial Subcapsular Domain. Journal of Immunology, 2012, 188, 569-577.	0.8	16
14	Correlation of Group C Meningococcal Conjugate Vaccine Response with B- and T-Lymphocyte Activity. PLoS ONE, 2012, 7, e31160.	2.5	3
15	Salmonella enterica Serovar Enteritidis Core O Polysaccharide Conjugated to H:g,m Flagellin as a Candidate Vaccine for Protection against Invasive Infection with <i>S.</i> Enteritidis. Infection and Immunity, 2011, 79, 4240-4249.	2.2	114
16	Adult Survivors of Invasive Pneumococcal Disease Exhibit Defective B Cell Function. Clinical Infectious Diseases, 2011, 52, 1133-1136.	5.8	5
17	Functional T-Cell Deficiency in Adolescents Who Experience Serogroup C Meningococcal Disease despite Receiving the Meningococcal Serogroup C Conjugate Vaccine. Vaccine Journal, 2010, 17, 1104-1110.	3.1	10
18	B-cell–T-cell activation and interaction in common variable immunodeficiency. Human Immunology, 2010, 71, 355-362.	2.4	22

ANDREW LEES

#	Article	IF	CITATIONS
19	Intact Bacteria Inhibit the Induction of Humoral Immune Responses to Bacterial-Derived and Heterologous Soluble T Cell-Dependent Antigens. Journal of Immunology, 2009, 182, 2011-2019.	0.8	15
20	Parameters Underlying Distinct T Cell-Dependent Polysaccharide-Specific IgG Responses to an Intact Gram-Positive Bacterium versus a Soluble Conjugate Vaccine. Journal of Immunology, 2009, 183, 1551-1559.	0.8	29
21	Evidence of a Functional B-Cell Immunodeficiency in Adults Who Experience Serogroup C Meningococcal Disease. Vaccine Journal, 2009, 16, 692-698.	3.1	11
22	Adults with a history of serogroup c neisseria meningitidis disease exhibit impaired in vitro immune responses. Journal of Infection, 2008, 56, 300-301.	3.3	0
23	Mannan-Abeta28conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. Journal of Neuroinflammation, 2008, 5, 42.	7.2	35
24	Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan. Vaccine Journal, 2008, 15, 1176-1187.	3.1	40
25	A Rapid Opsonic Assay for Measuring Killing of Bioluminescent <i>Staphylococcus epidermidis</i> . Hybridoma, 2008, 27, 487-491.	0.4	0
26	Aβ-Immunotherapy for Alzheimer's Disease Using Mannan–Amyloid-Beta Peptide Immunoconjugates. DNA and Cell Biology, 2006, 25, 571-580.	1.9	27
27	Versatile and efficient synthesis of protein–polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine, 2006, 24, 716-729.	3.8	33
28	Monoclonal antibodies to distinct regions of human myelin proteolipid protein simultaneously recognize central nervous system myelin and neurons of many vertebrate species. Journal of Neuroscience Research, 2006, 83, 415-431.	2.9	19
29	A Peptide Mimotope of Type 8 Pneumococcal Capsular Polysaccharide Induces a Protective Immune Response in Mice. Infection and Immunity, 2005, 73, 325-333.	2.2	51
30	Differential Regulation of IgG Anti-Capsular Polysaccharide and Antiprotein Responses to IntactStreptococcus pneumoniaein the Presence of Cognate CD4+T Cell Help. Journal of Immunology, 2004, 172, 532-539.	0.8	86
31	Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice. Infection and Immunity, 2004, 72, 196-208.	2.2	59
32	The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity. Cellular Immunology, 2004, 232, 64-74.	3.0	27
33	Rapid and complete adsorption of unconjugated protein from protein-polysaccharide conjugate vaccines. Vaccine, 2001, 19, 1547-1558.	3.8	9
34	Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine, 2001, 19, 2361-2368.	3.8	23
35	A Cryptococcal Capsular Polysaccharide Mimotope Prolongs the Survival of Mice with <i>Cryptococcus neoformans</i> Infection. Journal of Immunology, 2001, 166, 1087-1096.	0.8	105
36	Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. European Journal of Immunology, 2000, 30, 969-973.	2.9	13

ANDREW LEES

#	Article	IF	CITATIONS
37	B7 Requirements for Primary and Secondary Protein- and Polysaccharide-Specific Ig Isotype Responses toStreptococcus pneumoniae. Journal of Immunology, 2000, 165, 6840-6848.	0.8	46
38	Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides. Vaccine, 2000, 18, 1273-1281.	3.8	67
39	Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion. International Immunology, 1999, 11, 1693-1700.	4.0	48
40	Enhanced Protective Antibody Responses to PspA after Intranasal or Subcutaneous Injections of PspA Genetically Fused to Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2. Infection and Immunity, 1998, 66, 1513-1520.	2.2	48
41	Characterization of Early Activation Events in Cord Blood B Cells after Stimulation with T Cell-Independent Activators. Pediatric Research, 1998, 43, 496-503.	2.3	15
42	Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein—polysaccharide conjugate vaccines and immunological reagents. Vaccine, 1996, 14, 190-198.	3.8	124
43	T Cell-Independent Antigens Type 2. Annual Review of Immunology, 1995, 13, 655-692.	21.8	778
44	Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules. Vaccine, 1994, 12, 1160-1166.	3.8	27
45	Conjugation Chemistry. , 0, , 161-174.		2